ClinicalTrials.Veeva

Menu

ORthopaedic Trauma Anemia With Conservative Versus Liberal Transfusion (ORACL)

Indiana University logo

Indiana University

Status and phase

Completed
Phase 4

Conditions

Anemia

Treatments

Biological: Blood and blood products for transfusion

Study type

Interventional

Funder types

Other

Identifiers

NCT02972593
1402557771

Details and patient eligibility

About

The purpose of this study is to determine if there is a difference in outcomes between liberal transfusion (transfusing when hemoglobin drops below a set higher value number) and conservative transfusion (transfusing when hemoglobin drops below a set lower value number).

Full description

Transfusion of Orthopaedic trauma patients is routinely done in asymptomatic individuals as there is no accepted national standard or recommendations from the American Academy of Orthopaedic Surgeons or the Orthopaedic Trauma Association for what level of anemia is appropriate in an asymptomatic patient. Individual practitioners typically make this decision based on anecdotal experiences and expert opinion. No prospective study has been performed to date to answer this question in this patient population.

The null hypothesis of this proposed pilot study is that no difference will be seen with a liberal transfusion strategy to keep a patient's hemoglobin above 7 g/dL versus a conservative strategy to keep the patient's hemoglobin above 5.5 g/dL in patients asymptomatic at rest. The primary outcome of this pilot study will be infection; defined as postoperative wound infection (superficial or deep) or other perioperative infection but not surgical site (urinary tract infection or pneumonia). Deep infection is defined as the need for intravenous antibiotics or a return to surgery for debridement. Superficial infection is defined as the use of oral antibiotics only successfully treat a surgical site infection. Secondary outcomes will include pulmonary embolism, deep venous thrombosis, acute renal failure or insufficiency, nonunion, delayed union, compartment syndrome, osteomyelitis, nerve palsy, anoxic brain injury, cardiac ischemia or infarct, pancreatitis, or death, and the musculoskeletal functional assessment.

Enrollment

161 patients

Sex

All

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Trauma patients admitted to participating hospital with any Orthopaedic injury who have been determined to be stable by the Trauma Service (General Surgery) and are no longer within the resuscitation phase of initial treatment. This is defined as a normal urine output (greater than 0.5 ml/kg/hr) and a systolic blood pressure greater than 90 mmHg for greater than 6 hours without fluid bolus or transfusion during that time
  • Age 18-50
  • Hemoglobin less than 9 g/dL or expected drop below 9 g/dL with planned surgery

Exclusion criteria

  • Pregnant ( urine pregnancy test will be done as standard of care)
  • Prisoner
  • Head injury (Glasgow Coma Scale less than 8 over 48 hours from presentation)
  • Known cardiac (coronary artery disease, atrial fibrillation, stent placement, congestive heart failure), renal (acute or chronic renal insufficiency or failure, defined as having Serum Creatinine >1.2 at time of enrollment), liver (Childs C cirrhosis) or pulmonary disease (chronic obstructive pulmonary disease, abnormal pulmonary function tests or history of poor pulmonary function from any cause including acute traumatic conditions such as ARDS)
  • Unlikely to follow up in the surgeon's estimation
  • Sickle Cell Anemia
  • History of cancer
  • Preexisting weakness, paresthesias, deformities, or other conditions which might affect functional outcome in the surgeon's opinion
  • Spinal cord injury
  • Patients with burns expected to require operative treatment
  • COVID positive

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

161 participants in 2 patient groups

Liberal
Other group
Description:
Blood and blood products for transfusion. Transfusion will be done to keep Hgb \>7 g/dL.
Treatment:
Biological: Blood and blood products for transfusion
Conservative
Other group
Description:
Blood and blood products for transfusion. Transfusion will be done to keep Hgb \> 5.5 g/dL.
Treatment:
Biological: Blood and blood products for transfusion

Trial documents
1

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems